Exhibit 10.3[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDManufacturing AgreementBetweenAntares Pharma, Inc.andAMAG Pharmaceuticals, Inc.[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDMANUFACTURING AGREEMENTThis Manufacturing Agreement (“Agreement”) is made and entered into as of the 20th day of March, 2018 (the “EffectiveDate”) by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300,Ewing, NJ 08628 (“Antares”), and AMAG Pharmaceuticals, Inc., a Delaware corporation, with a corporate address at 1100Winter Street, Waltham, MA 02451 (“AMAG”). Antares and AMAG are sometimes referred to herein individually as a “Party”and collectively as the “Parties”.RecitalsWHEREAS, AMAG is engaged in discovering, developing and marketing pharmaceutical products, including the Drug (asdefined below);WHEREAS, Antares is engaged in the research and development of certain drug delivery devices, including auto-injectionsystems and the development and marketing of pharmaceutical products;WHEREAS, AMAG Pharma USA, Inc. (f/k/a Lumara Health, Inc., (“AMAG USA”)), which was acquired by AMAG onNovember 12, 2014 and is a wholly-owned subsidiary of AMAG, and Antares entered into a certain Development and LicenseAgreement (defined below) under which Antares granted AMAG USA an exclusive, worldwide license to Antares’ VIBEXQuickShot (QS) auto-injection system or similar Device (defined below) for use with the Drug, and further under which Antaresand AMAG USA agreed to collaborate to develop such a product;WHEREAS, contemporaneously with the execution of this Agreement, Antares, AMAG and AMAG USA are entering intoa First Amendment to Development and License Agreement, pursuant to which, among other amendments set forth therein,AMAG USA assigned, and AMAG assumed, the rights and responsibilities under the Development and License Agreement (the“First Amendment to Development and License Agreement”);WHEREAS, AMAG (as the permitted assignee of the Development and License Agreement) and Antares agreed under theDevelopment and License Agreement to enter into this Agreement and, whereby it will provide Antares or its Subcontractor(defined below) with Prefilled Syringes (defined below) containing the Drug and Antares or it Subcontractor will incorporate thePrefilled Syringes into Devices to produce finished Products (defined below) and sample Products to supply AMAG’srequirements for such Products and sample Products; andWHEREAS, AMAG wishes to purchase, and Antares wishes to supply, AMAG’s requirements of the Trainers (definedbelow) on the terms set forth in this Agreement.NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained in thisAgreement, the Parties hereto agree as follows:- 1 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDARTICLE 1INTERPRETATION1.1Definitions. Capitalized terms used in this Agreement and not otherwise defined in this Section 1.1 shall have the meaningsset out in the Development and License Agreement. The following terms shall, unless the context otherwise requires, havethe respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:“[]” has the meaning specified in Section 3.2(c);“[]” has the meaning specified in Section 3.2(c);[]“Agreement” has the meaning specified in the Preamble;“AMAG” has the meaning specified in the Preamble;“AMAG Indemnitees” has the meaning specified in Section 9.2;“AMAG USA” has the meaning specified in the Recitals;“AMAG Quality Tasks” means AMAG’s quality, testing and release obligations set forth in Section 2.6(b) and in the QualityAgreement;“Annual Product Review Report” means the annual product review report as described in Title 21 of the United States Code ofFederal Regulations, Section 211.180(e);“Annual Report” means the annual report as described in Title 21 of the United States Code of Federal Regulations, Section314.81(b)(2);“Antares” has the meaning specified in the Preamble;“Antares’ Fully Burdened Manufacturing Costs” means those costs actually incurred by Antares related directly to theacquisition of materials and their conversion into Products, sample Products or Trainers, as the case may be. [];“Antares Indemnitees” has the meaning specified in Section 9.1;“Batch Record” means a detailed, step-by-step description of the entire assembly, packaging and labelling process for theProducts and sample Products which explains how such Products or sample Products (as the case may be) were assembled,packaged and labelled, indicating specific types and quantities of Components, additional materials, processing parameters, in-process quality controls, and other relevant controls;- 2 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED“Binding Forecast” has the meaning specified in Section 3.2(a);“[]” has the meaning specified in Section 3.2(c);“Business Day” means a day other than a Saturday, Sunday or a day that is a federal holiday in the United States;“Calendar Quarter” means a three-month period ending on March 31, June 30, September 30 or December 31;“Calendar Year” means a calendar year occurring after the Effective Date; provided, however, the first Calendar Year means theperiod from the Effective Date up to and including December 31 of the same calendar year in which the Effective Date occurs;“[]” has the meaning specified in Section 3.2(c);“Certificate of Analysis (Device)” means a document signed by an authorized representative of Antares or the Subcontractorthat conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testingmethods applied to, the quantity of each of the Major Device Components manufactured by or on behalf of Antares pursuant tothis Agreement, and the results of such testing, and (ii) certifies that such quantity of each of the Major Device Components wasmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications;“Certificate of Analysis (PFS Manufacture)” means a document signed by an authorized representative of AMAG, its agentor its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes thespecifications for, and testing methods applied to the Drug manufactured by or on behalf of AMAG pursuant to this Agreement,and the results of such testing, and (ii) certifies that such quantity of Drug was manufactured in accordance with cGMP, all otherApplicable Laws, and the Product Specifications;“Certificate of Analysis (PFS ID Testing)” means a document signed by an authorized representative of AMAG, its agent orits permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that describes thespecifications for, and testing methods applied to, the Drug manufactured by or on behalf of AMAG pursuant to this Agreementfor identification of the Drug, and the results of such testing;“Certificate of Analysis (Product)” means a document signed by an authorized representative of AMAG, its agent or itspermitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes thespecifications for, and testing methods applied to, the quantity of Product and/or sample Product manufactured by or on behalf ofAntares pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of Product and/or sampleProduct was- 3 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications;“Certificate of Conformance (Device)” means the document provided to AMAG by Antares or the Subcontractor thatconducted the applicable review, as the case may be, that certifies each batch of each of the Major Device Components wasmanufactured in compliance with the cGMP, all other Applicable Laws, and the Product Specifications;“Certificate of Conformance (Product)” means the document provided to AMAG by Antares or the Subcontractor thatconducted the applicable review, as the case may be, that certifies each batch of Product and/or sample Product was assembled,packaged and labelled in compliance with the cGMP, all other Applicable Laws, and the Product Specifications;“cGMP” means current good manufacturing practice and standards as provided for (and as amended from time to time) in the“Current Good Manufacturing Practice Regulations” of the U.S. Code of Federal Regulations Title 21 (21CFR§4;21CFR§210/211 and 21CFR§820) and in European Community Council Directive 93/42/EEC concerning medical devices, anyU.S., European, or other applicable laws, regulations or respective guidance documents now or subsequently established by agovernmental or regulatory authority, and any arrangements, additions, or clarifications;“Change Order” has the meaning specified in Section 4.2(b);“Commercially Reasonable Efforts” means, with respect to each Party, such efforts and commitment of resources inaccordance with [] that such Party []. As used in this definition of “Commercially Reasonable Efforts”, “reasonable”shall be measured by []. References in this Agreement to “commercially reasonable” and similar formulations shall bedeemed to incorporate the standard set forth in this definition of “Commercially Reasonable Efforts”;“Components” means, collectively, [];“Damages” has the meaning specified in Section 9.1;“Deficiency Notice” has the meaning specified in Section 5.1(a);“Delivery Date” means the delivery date of a Purchase Order of Products, sample Products or Trainers as agreed upon by theParties pursuant to Section 3.2(b)(i) or Antares’ proposed date if AMAG does not respond within the [] set forth in Section3.2(b)(i);“Development and License Agreement” means that certain Development and License Agreement entered into by andbetween the Parties dated as of September 30, 2014, as amended by the First Amendment to the Development and LicenseAgreement, and as further amended by the Parties from time to time;- 4 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED“Device” means the VIBEX QS auto-injection system device, consisting of the Major Device Components, designed anddeveloped to incorporate a Prefilled Syringe for delivery of the Drug, and any improvements or modifications thereof madepursuant to the Development and License Agreement, or such other Antares-proprietary device as agreed to by Antares designedand developed to deliver the Drug pursuant to the Development and License Agreement, as further set forth on Exhibit B. Forgreater certainty, the Major Device Components are intended to be assembled with the Prefilled Syringe to produce a finishedProduct;“DHF” has the meaning specified in the Development and License Agreement;“DMF” has the meaning specified in the Development and License Agreement and is expanded to further clarify that a DMF isequivalent to an “MAF” or Master File;“Drug” means 17-alpha hydroxyprogesterone caproate;“Effective Date” has the meaning specified in the Preamble;[]“Excess Order” has the meaning specified in Section 3.2(b)(i);“Firm Orders” means any Purchase Order accepted by Antares pursuant to Section 3.2(b)(i) (as evidenced by an OrderAcceptance), including any Excess Orders agreed to by Antares in an Order Acceptance, with the Delivery Date as set forth inSection 3.2(b)(i);“First Amendment to the Development and License Agreement” has the meaning specified in the Recitals;“Force Majeure Event” has the meaning specified in Section 12.4;“Forecast” has the meaning specified in Section 3.2(a);“[]” has the meaning specified in Section 4.6;“[]” has the meaning specified in Section 3.2(c);“[]” has the meaning specified in Section 3.2(c);“Invoice” has the meaning specified in Section 4.2(a);“[]” has the meaning specified in Section 3.2(c);“Latent Defects” has the meaning specified in Section 5.1(a);- 5 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED“Long Lead Time Materials” means [], a description of which are set forth on Exhibit A (as such exhibit may be amendedfrom time to time by the mutual written agreement of the Parties), [];“Major Device Components” means the following Components of the Device: [].“Manufacture(d) at Risk” has the meaning specified in Section 3.7(a);“Manufacturing Services” means the manufacturing, quality control and quality assurance, storage, labelling, packaging,assembly and related services, to be performed by Antares or its Subcontractor as contemplated in this Agreement and describedin the Specifications and the Quality Agreement, required to manufacture Devices and produce and supply Trainers, Products andsample Products from such Devices, Prefilled Syringes and Components. For the avoidance of doubt, the “ManufacturingServices” specifically excludes the AMAG Quality Tasks and all other services, activities or tasks to be performed by or on behalfof AMAG set forth in this Agreement or as otherwise described in the Specifications or the Quality Agreement;“Manufacturing Site” means [] or such other facility owned and operated by Antares or a Subcontractor on behalf ofAntares under this Agreement [].“Non-Binding Forecast” has the meaning specified in Section 3.2(a);“Non-Cancellable Non-Returnable Materials” or “NCNR Materials” means [];[]“Order Acceptance” has the meaning specified in Section 3.2(b)(i);“Other Approved Antares Product” has the meaning specified in Section 4.6(a);“Parties” and “Party” have the meanings specified in the Preamble;“Person” means any natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, anyGovernmental Authority or any other entity or organization;“[]” has the meaning specified in Section 2.1(b);“Prefilled Syringe” means the prefilled syringe containing the formulated Drug for incorporation into the Device, as further setforth in the Product Specifications;“Prior Orders” has the meaning specified in Section 3.2(c);“Product(s)” means the fully packaged Device for auto-injection delivery of the Drug incorporating a Prefilled Syringe and otherapplicable Components listed on Exhibit B- 6 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDhereto, as such exhibit may be amended from time to time by the mutual written agreement of the Parties;“Product Specifications” means, as set forth on Exhibit B hereto, for each Product, with AMAG having primary responsibilitywith respect to the Drug and Prefilled Syringe, and Antares having primary responsibility with respect to the Devices andComponents, the following documents relating to such Product:(a)specifications for Devices, Prefilled Syringes and Components;(b)the Product Specifications; and(c)storage, packaging, prescribing information and label specifications and requirements; andall as updated, amended and revised from time to time by the Parties in writing in accordance with the terms of this Agreement,and in all cases including compliance with all Applicable Laws and the Quality Agreement;“Quality Agreement” has the meaning specified in Section 2.6(a);“Recall” means any action (i) by AMAG to recover title to or possession of quantities of the Products, sample Products and/orTrainers sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products, sample Productsand/or Trainers) from the market); or (ii) by any Regulatory Authorities to detain or destroy any of the Products and/or the sampleProducts. Recall shall also include any action by either Party to refrain from selling or shipping quantities of the Products, sampleProducts and/or Trainers to third parties which would have been subject to a Recall if sold or shipped;“Safety Stock” has the meaning specified in Section 3.6(a);“Second Source Supplier” has the meaning specified in Section 3.9;“[]” has the meaning specified in Section 2.1(b);“Specifications” means the Product Specifications with respect to the Product and sample Product, and the TrainerSpecifications with respect to the Trainers, as the case may be;“Subcontractor” has the meaning specified in Section 2.1(b);“Supply Failure” has the meaning specified in Section 3.5(a);“Supply Failure Remedy Option” has the meaning specified in Section 3.5(b);[]“Term” has the meaning specified in Section 7.1;- 7 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED“[]” has the meaning specified in Section 3.2(c);“Third Person” means any Person or entity other than AMAG, Antares, or an Affiliate or sublicensee of either Party with respectto this Agreement and/or the Development and License Agreement.“Third Person Claim” has the meaning specified in Section 9.1;“Trainer” means a reusable version of the Product that does not incorporate the Prefilled Syringe and that is to be used todemonstrate how to operate the Product;“Trainer Specifications” means, as set forth on Exhibit C hereto, for each Trainer, the requirements and print/part numbersdocuments relating to such Trainer, as updated, amended and revised from time to time by or on behalf of the Parties, and in allcases including compliance with all Applicable Laws;“Transfer Price” has the meaning specified on Exhibit D hereto;“U.S. GAAP” has the meaning specified in the definition of Antares’ Fully Burdened Manufacturing Costs; and“VAT” means, in relation to any jurisdiction within the European Union, the value added tax provided for in Council Directive2006/112/EC and charged under the provisions of any national legislation implementing that directive or Council Directive77/388/EEC together with legislation supplemental thereto and, in relation to any other jurisdiction, the equivalent tax (if any) inthat jurisdiction.“Yield” has the meaning specified in Section 2.10.1.2Currency. Unless otherwise indicated, all monetary amounts are expressed in this Agreement in the lawful currency of theUnited States of America.1.3Sections and Headings. The division of this Agreement into Articles, Sections, subsections and Exhibits and the insertionof headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwiseindicated, any reference in this Agreement to an Article, Section or Exhibit refers to the specified Article, Section or Exhibitto this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressionsrefer to this Agreement and not to any particular part, Section, Exhibit or the provision hereof.1.4Singular Terms. Except as otherwise expressly provided herein or unless the context otherwise requires, all references tothe singular shall include the plural and vice versa.1.5Exhibits. The following Exhibits are attached to, incorporated in and form part of this Agreement:- 8 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDExhibit A - Long Lead Time MaterialsExhibit B - Product SpecificationsExhibit C - Trainer SpecificationsExhibit D - Transfer PriceExhibit E - Quality AgreementExhibit F - Batch Numbering Expiration DatesExhibit G - Retained SamplesExhibit H - Initial ForecastExhibit I - Redundancy PlanExhibit J - []Exhibit K - AMAG EquipmentExhibit L - Form of Change OrderARTICLE 2 MANUFACTURING AND SUPPLY OBLIGATIONS2.1Manufacturing Services.(a)Starting on the Effective Date, Antares or its Subcontractor shall provide the Manufacturing Services in order tomanufacture Devices, Products, sample Products and Trainers exclusively for AMAG for the Territory, all inaccordance with the Specifications, Applicable Laws, Quality Agreement and this Agreement. For the avoidance ofdoubt, subject to, and without limiting or amending the exclusivity restrictions and confidentiality obligations set forthin Section 6.1 and ARTICLE 17 of the Development and License Agreement, respectively, Antares or itsSubcontractor may manufacture the VIBEX QS device or other devices (other than the Device) for itself or otherPersons. Antares or its Subcontractor shall conduct all Manufacturing Services at the Manufacturing Site and maychange the Manufacturing Site for the Products, sample Products and Trainers only with the prior written consent ofAMAG, such consent not to be unreasonably withheld, conditioned or delayed (provided that, Antares or itsSubcontractor shall provide a minimum of [] prior written notice of such change of Manufacturing Site).(b)[].(c)Antares shall have the right to specify the final assembly packaging and labeling process (subject to AMAG’sprovision of label content) for Products, sample Products and Trainers, including the combination of the componentsthereof, in accordance with the Specifications and the Quality Agreement.2.2Prefilled Syringes.(a)AMAG or its designee(s) will be responsible for manufacture, formulation and testing of any Drug and the PrefilledSyringe for assembly with the Device into the Product- 9 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDand sample Product by Antares or its Subcontractor and for final Product and/or sample Product release for sale,commercialization or use by a Third Person. AMAG shall supply Prefilled Syringes to Antares or its Subcontractor in accordancewith the terms of this Section 2.2 AMAG will have sole decision-making authority regarding the use of a Third Person tomanufacture any aspect of the Drug and the Prefilled Syringes. AMAG shall conduct release testing for Prefilled Syringes. Antaresor its Subcontractor shall use and store all Prefilled Syringes provided hereunder in accordance with AMAG’s reasonableinstructions, the Quality Agreement, cGMPs and all other Applicable Laws at Antares’ or its Subcontractor’s storage facility at theManufacturing Site. Antares or its Subcontractor shall conduct a visual inspection of all Prefilled Syringes received at theManufacturing Site not later than [] after the date of receipt in accordance with the mutually agreed upon procedures. Antaresor its Subcontractor shall promptly (and in any event within [] following completion of applicable inspection) notify AMAG inwriting of any visual inspection failure of the Prefilled Syringes. Antares shall not allow any lien or other security interest to beimposed on the Prefilled Syringes by Antares or its Subcontractor or as a result of Antares or its Subcontractor action or inaction.Antares or its Subcontractor shall use all quantities of Prefilled Syringes provided hereunder for the sole purpose of performing theManufacturing Services on behalf of AMAG and not for any other use or purpose.(b)The Parties acknowledge and agree that title to and risk of loss of all Prefilled Syringes shall at all times belong toand remain in AMAG; provided that, subject to the limitations on liability set forth in this Section 2.2(b), in the eventof loss or damage of any Prefilled Syringes while they are at the Manufacturing Site, Antares shall be onlyresponsible for the replacement costs (as evidenced by AMAG invoices) of such Prefilled Syringes if the damage,loss, theft or destruction was caused by the negligent act or omission or the willful misconduct of Antares or itsSubcontractor. For the avoidance of doubt, Antares shall not be responsible for any damage, loss or destruction tothe Prefilled Syringes resulting from damage, loss or destruction caused by the reasonable amount of PrefilledSyringes damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield) or obsolescencedue to changes in the manufacturing process. Not later than [] following the end of each Calendar Year, AMAGshall provide Antares with an invoice and accounting of the Prefilled Syringes that were damaged or destroyedduring the prior year (following notification from Antares of such damage or destruction). Payment of undisputedportions of such invoice shall be due [] from Antares’ receipt of such invoice. []. All Prefilled Syringes inAntares’ possession shall be subject to disposition by AMAG upon expiration or termination of this Agreement, andin either such event, Antares or its Subcontractor shall deliver the Prefilled Syringes to AMAG or its designee, atAMAG’s- 10 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDreasonable expense. AMAG shall be solely responsible and reimburse Antares for all reasonable costs and expenses associatedwith the storage of the Prefilled Syringes at Antares’ or its Subcontractor’s storage facility at the Manufacturing Site following theexpiration or termination of this Agreement. Antares agrees to reasonably cooperate with AMAG, at AMAG’s expense, in thefiling of any UCC financing statements relating to the Prefilled Syringes as may be required under Applicable Laws.(c)All shipments of Prefilled Syringes made by AMAG or its designee to Antares or its Subcontractor hereunder will bedelivered [] Antares’ or its Subcontractor’s Manufacturing Site unless otherwise mutually agreed. [].2.3Devices. Antares or its Subcontractor shall manufacture and test all Devices as specified by the Product Specificationsprior to using such Devices to manufacture Products and sample Products. Antares or its Subcontractor shall properlystore the Devices at Antares’ or its Subcontractor’s storage facility at the Manufacturing Site pursuant to cGMP andApplicable Law.2.4Components. Antares or its Subcontractor shall purchase and inspect all Components as specified by the Specificationsprior to using such Components to manufacture Products, sample Products and Trainers. Antares or its Subcontractorshall properly store the Components at Antares’ or its Subcontractor’s storage facility at the Manufacturing Site pursuantto cGMP and Applicable Law.2.5Assembly of Devices, Prefilled Syringes and Components. Antares or its Subcontractor shall assemble Devices,Prefilled Syringes and Components into Products, sample Products and Trainers (as applicable) in accordance with theterms of this Agreement.2.6Quality Control and Quality Assurance.(a)On or about the date hereof, the Parties shall amend and restate the Quality Agreement entered into on May 16,2016 between the Parties covering the Product, sample Products, Trainers, the Device and the Prefilled Syringes, asset forth in the form of Amended and Restated Quality Agreement attached hereto as Exhibit E (as amended andrestated, the “Quality Agreement”). The Parties shall review the Quality Agreement and shall modify the samefrom time to time as detailed in the Quality Agreement as necessary through a written amendment to the QualityAgreement signed by an authorized representative on behalf of each of the Parties. The Parties shall perform thequality control and quality assurance testing specified in Section 2.6(b) and the Quality Agreement. The Parties shallperform Product, sample Product and Trainer review and final release of the Product, sample Product and Trainersfor sale in accordance with Section 2.6(b) and the Quality Agreement, the Specifications and Applicable Laws.- 11 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(b)Subject to, and as more fully set forth in, the Quality Agreement, the Parties agree as follows:[].2.7Labelling and Packaging. Antares or its Subcontractor shall label and package the Products, sample Products andTrainers as set out in the Specifications. AMAG shall be responsible for the cost of artwork development for the Products,sample Products and Trainers. In addition, Antares or its Subcontractor shall arrange for and implement (a) the imprintingof batch numbers and expiration dates for each batch of Products and sample Products shipped, and (b) the imprinting ofbatch numbers for each batch of Trainers shipped. Such batch numbers and expiration dates shall be affixed on theProducts, sample Products and Trainers and, on the shipping carton of each Product, sample Product and Trainer asoutlined in the Specifications and, as required by cGMPs and Applicable Laws. The system used by Antares or itsSubcontractor for batch numbering and expiration dates is detailed in Exhibit F hereto. AMAG shall be solely responsiblefor the content of the labelling and the provision of such content. Notwithstanding anything to the contrary in thisAgreement, Antares’ obligation to perform the Manufacturing Services is subject to AMAG’s reasonably timely approvaland provision of all labelling content. AMAG may, in its sole discretion, make changes to labels, product inserts and otherpackaging for the Products, sample Products and Trainers, which changes shall be submitted by AMAG to all applicableRegulatory Authorities from which approval of such changes is required. AMAG shall be responsible for the cost oflabeling obsolescence due to changes to such labeling made by AMAG, including the reasonable cost of disposal andreplacement of packaging materials. Antares’ name shall appear on the label or anywhere else on the Products, sampleProducts and Trainers as reasonably agreed upon by the Parties, unless: (i) prohibited by Applicable Laws; or (ii) theParties otherwise agree in writing.2.8Validation Activities. Antares or its Subcontractor will be responsible for the development and approval of the validationprotocols for analytical methods and manufacturing processes (including packaging processes) for the Products, sampleProducts and Trainers as described in the Specifications in accordance with the Quality Agreement and shall be approvedby AMAG prior to execution thereof. [].2.9Retained Samples. Antares or its Subcontractor shall retain sufficient quantities of shipped Products, sample Products,Devices and Components as retained repository samples as required under the Quality Agreement and Applicable Laws atAMAG’s sole cost and expense and as set forth in Exhibit G. Such retained samples shall minimally represent [] thenumber of samples necessary to re-execute chemical release testing and will be maintained in a suitable storage facility atAntares’ or its Subcontractors’ Manufacturing Site until [] or such longer period as may be required by ApplicableLaws. All such samples shall be available for inspection by AMAG at reasonable intervals upon reasonable- 12 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDnotice. AMAG shall advise Antares of the required quantities of shipped Products, sample Products, Devices and Componentsthat AMAG desires to be retained. Antares shall invoice AMAG for the costs associated with performing these activities.2.10Yield. [].ARTICLE 3 ANTARES’ SUPPLY OF PRODUCT3.1Supply of Product.(a)Commencing on the Effective Date and continuing during the Term, Antares shall manufacture and supply, or havemanufactured and supplied by its Subcontractor, all quantities of the Products, sample Products and Trainersordered by AMAG in the Territory pursuant to this Agreement. Commencing on the Effective Date and during theTerm, AMAG shall commit to purchase its entire requirements of Product(s), sample Products and Trainers for salein the Territory from Antares.(b)The Parties agree that in the event that AMAG seeks Regulatory Approval for the Product, sample Product orTrainers for a country outside of the United States, the Parties will enter into an amendment to this Agreement settingforth the terms and conditions of supply of Products, sample Products or Trainers for that country.3.2Orders and Forecasts.(a)Rolling Forecasts. On or before the [] after the Effective Date, AMAG shall provide Antares with an updatedwritten [] rolling forecast of the volume of Product, sample Product and Trainers that AMAG then anticipateswill be required to be produced and delivered to AMAG during [] (the “Forecast”). The initial Forecast isattached hereto as Exhibit H. [] of each Forecast shall constitute a firm order and be a binding commitment onAMAG to purchase the volume of Product, sample Product and Trainers set forth therein (the “Binding Forecast”).[] of each Forecast shall be non-binding (the “Non-binding Forecast”). The Non-binding Forecast shall beprepared in good faith by AMAG and represent AMAG’s reasonable expectation of its requirements of Product,sample Product and Trainers for [] of such Forecast. Each Forecast shall include an estimated delivery date ofthe Prefilled Syringes to Antares or its Subcontractor (such estimate to be provided by AMAG in good faith).(b)Purchase Orders.(i)To order Products, sample Products and Trainers for supply by Antares or its Subcontractor under thisAgreement, AMAG shall submit to Antares a Purchase Order (which is deemed binding on AMAG)complying with the other applicable terms of this Agreement []. Not later than [] after receipt of aPurchase- 13 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDOrder, Antares shall confirm in writing its receipt of the Purchase Order (“Order Acceptance”) and the proposed delivery dateto AMAG in writing; provided that Antares may reject any Purchase Order not consistent with the requirements set forth in thisAgreement, including this Section 3.2(b)(i). AMAG shall notify Antares within [] after receipt of the Order Acceptance if suchproposed delivery date is unacceptable for AMAG, and in such event, the Parties shall promptly discuss and seek to agree on analternative delivery date. If AMAG does not respond within such [] period, the proposed date will be the confirmed deliverydate. Antares shall not be obligated to fill any portion of any Purchase Order to the extent the volumes in such Purchase Orderexceed the volumes set forth in the most recent Binding Forecast (such excess amount, the “Excess Order”). For any PurchaseOrder that contains an Excess Order, Antares shall notify AMAG in the Order Acceptance whether Antares and/or itsSubcontractors will fulfill such Excess Order (or part thereof) and the expected delivery date for fulfillment. The decision to fulfillany Excess Order may be made by Antares in its sole discretion and Antares shall not be liable for any failure to deliver anyProduct, sample Product or Trainers set forth in any Excess Order; provided that Antares meets its obligations consistent with theBinding Forecast. AMAG’s failure to deliver a Purchase Order consistent with the volumes of Product, sample Product and/orTrainers under any Binding Forecast, shall not relieve AMAG of its obligation to purchase such volumes of Product, sampleProduct and/or Trainers. The terms of this Agreement shall be controlling and any additional or inconsistent terms or conditionscontained on any Forecast, Purchase Order, Order Acceptance, invoice or similar documentation given or received by the Partiesshall have no effect and such terms and conditions are expressly disclaimed and excluded.(ii)AMAG and Antares acknowledge and agree that any minor difference between the quantity of ordered anddelivered quantity of Product, sample Product or Trainers (as the case may be) that falls within applicableindustry standards shall be accepted by AMAG as delivery in full of the ordered quantities set forth on anyFirm Order and shall not be deemed a shortage as set forth in Section 5.1(c), but in no event shall the quantitydelivered deviate from the quantity ordered by more than: [].(iii)Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antaresshall only be responsible for producing and delivering to AMAG that portion (up to the entire quantity) ofProducts and sample Products requested pursuant to a Purchase Order for which Antares or its Subcontractor(as the case may be) possesses, at least [] prior to the Delivery Date, a sufficient stock of inventory ofPrefilled Syringes necessary to- 14 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDfulfill such order (including any additional quantity of Prefilled Syringes necessary to account for Prefilled Syringes reasonablyexpected to be damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield)) and the Certificate ofAnalysis (PFS Manufacture) relating thereto. In the event that Antares or its Subcontractor (as the case may be) has not receiveda sufficient stock of Prefilled Syringes by the dates set forth in the previous sentence, Antares or its Subcontractor shall (A)manufacture and deliver such number of Products and sample Products for which Antares or its Subcontractor (as the case maybe) has Prefilled Syringes in accordance with the schedule set forth in the Firm Order, and (B) as soon as practicable (and nomore than [] following receipt of the Prefilled Syringes required for such Firm Order, Antares or its Subcontractor shallmanufacture and deliver the Products and sample Products in such order taking into account any Products and sample Productsmanufactured and delivered pursuant to subsection (A).(iv)Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antaresshall not be responsible for delay in the delivery of quantity of Products, sample Products or Trainers (as thecase may be) set forth in any Firm Order to the extent such delay is caused primarily due to AMAG’s failure tofulfill the AMAG Quality Tasks to enable Antares and/or its Subcontractor to timely perform theManufacturing Services.(c)Prior Orders. [].3.3Minimum Orders. The quantity of Products, sample Products or Trainers (as the case may be) ordered by AMAG fromAntares in each shipment (as set forth in a Purchase Order) must be equal to or greater than [] units for each type ofProduct, sample Product and Trainers ordered. Such minimum order quantity may be updated from time to time by amutual written agreement of the Parties. For avoidance of doubt, except for any Purchase Orders placed by AMAGand/or quantities set forth in the Binding Forecast, nothing in this Agreement requires AMAG to purchase any particularquantity of Products from Antares.3.4Shipments.(a)Shipments of Products, sample Product and Trainers shall be made EXW (as such term is defined in INCOTERMS2010) Antares’ or its Subcontractor’s (as the case may be) designated shipping location unless otherwise mutuallyagreed. The Parties acknowledge and agree that delivery of Products, samples Products and/or Trainers under thisAgreement shall be deemed to be made once the Products, samples Products and/or Trainers (as the case may be)are made available at Antares’ or its Subcontractor’s (as the case may be) designated shipping location. [].AMAG shall pay for shipping. AMAG shall arrange for insurance and shall select the freight- 15 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDcarrier to ship Products, sample Products and Trainers. Antares shall not be responsible for the payment of such insurance.Products, sample Products and Trainers shall be transported in accordance with the Specifications.(b)Prior to release for distribution, sale or use by AMAG pursuant to Section 2.6(b)(v)(D), AMAG, its agent or itspermitted subcontractor shall test each batch of Products, sample Products and Trainers manufactured under thisAgreement in accordance with Section 2.6(b)(v)(D). AMAG, its agent or its permitted subcontractor shall conductall such testing in accordance with the procedures and using the analytical testing methodologies set forth in theSpecifications, the Quality Agreement and Applicable Laws. All Products, sample Products and Trainers shipped byAntares or its Subcontractor to AMAG or AMAG’s designee, including its packaging, shall meet all applicableexport and customs laws, regulations and like requirements for the United States.3.5Supply Failure.[].3.6Safety Stock.(a)At AMAG’s sole cost and expense, Antares or its Subcontractor will maintain and make available to AMAG asafety inventory of the Major Device Components necessary to assemble the Devices in the quantities set forth in thisSection 3.6(a) at Antares or its Subcontractor’s Manufacturing Site in accordance with this Section 3.6 (“SafetyStock”).(i)[].(ii)[].(b)With respect to the initial Safety Stock (as set forth in Section 3.6(a)(i)) or any increase in Safety Stock pursuant toSection 3.6(a)(ii), upon the completion of the manufacture of such Safety Stock and delivery to AMAG of theCertificate of Analysis (Device) and the Certificate of Conformance (Device) applicable to such Safety Stock,Antares shall invoice AMAG for its [] pursuant to invoicing and payment terms set forth in Section 4.2.(c)With respect to any reduction in the Safety Stock pursuant to Sections 3.6(a)(ii) or 3.6(d), to the extent suchreduced quantities of Safety Stock are used in the manufacture of fully finished Products and/or sample Products,then Antares shall credit any amount previously paid by AMAG with respect to such reduced quantity in SafetyStock in the Invoice issued to AMAG pursuant to Section 4.2 for such fully finished Product and/or sample Product.- 16 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(d)Antares or its Subcontractor shall manage the Safety Stock as part of its overall inventory and use the Safety Stockto fulfill its obligations pursuant to a Firm Orders on a first in/first out basis. As such inventory of Safety Stock is usedas part of the Manufacturing Services of Product and/or sample Product, Antares shall use CommerciallyReasonable Efforts to replenish the Safety Stock to the level set forth in Section 3.6(a)(i) (as adjusted pursuant toSection 3.6(a)(ii)) within [] of receipt of such Firm Order.(e)Title and risk of loss of the Safety Stock shall transfer to AMAG upon the delivery to AMAG of the Certificate ofConformance (Device) and Certificate of Analyses (Device) for the applicable shipment of such Safety Stock fromAntares’ Subcontractor that manufactured such Safety Stock. Antares shall not be responsible for any insurance withrespect to the risk of loss of such Safety Stock.(f)In the event any Safety Stock expires, Antares or its Subcontractor shall dispose of or destroy such Safety Stock inaccordance with the Quality Agreement. AMAG shall reimburse Antares for any costs or expenses incurred (withoutmarkup) in connection with such disposal or destruction.(g)Notwithstanding the quantities set forth in Section 3.6(a), Antares or its Subcontractor shall maintain and store theSafety Stock during the Term of this Agreement, provided that during the last [] before expiration or terminationof this Agreement, Antares or its Subcontractor is only required to maintain that amount of Safety Stock as isrequired to deliver amounts set forth in the then-current Forecast(s) until such expiration or termination date. AMAGshall reimburse Antares for any reasonable costs or expenses incurred (without markup) in connection withmaintaining or storing the Safety Stock.3.7Manufacture at Risk.(a)In the event AMAG desires for Antares and/or its Subcontractor to initiate Manufacturing Services with respect toany Product or sample Product prior to the receipt of the Certificate of Analysis (PFS Manufacture) and theCertificate of Analysis (PFS ID Testing) (“Manufacture(d) at Risk”), AMAG shall deliver written notice of such toAntares. Notwithstanding anything in this Agreement to the contrary, Antares shall not be required to perform anyManufacturing Services with respect to the Product or sample Product until Antares receives (i) such written noticeof AMAG’s intention to Manufacture at Risk as set forth in the first sentence of this Section 3.7(a), or (ii) theCertificate of Analysis (PFS Manufacture) and the Certificate of Analysis (PFS ID Testing).(b)[].- 17 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED3.8Redundancy Plan. Antares shall, at the Party’s respective costs set forth on Exhibit I, develop, implement and maintain anthe redundancy plan for molds, tooling and assemblies for the manufacturing of the Devices set forth on Exhibit I.3.9Qualification of Second Source Supplier(s). Antares shall, upon AMAG’s written request provided to Antares and atAMAG’s cost (as set forth in this Section 3.9), identify and reasonably verify the suitability of one or more Third Personsas a “backup” supplier of Devices (each, a “Second Source Supplier”) in addition to Antares’ then-current supplier ofDevices (whether Antares or its then-current Subcontractor). Within [] following the receipt of such written request,the Parties will negotiate in good faith a budget for the costs and expenses associated with the Second Source Supplier,including all costs and expenses for the establishment and qualification thereof. Within [] following the agreement byboth Parties of such budget, Antares will use Commercially Reasonable Efforts to establish and qualify such SecondSource Supplier; provided, however, that the Joint Project Team under the Development and License Agreement mayagree to extend such time periods. AMAG shall have the right to propose a Second Source Supplier and Antares shallhave the right to consent to such Second Source Supplier, which consent shall not be unreasonably withheld or delayed.Within [] of a receipt of an invoice thereof, AMAG shall reimburse Antares for all documented costs and expenses(without markup) associated with the Second Source Supplier, including all documented costs and expense for theestablishment and qualification thereof; provide that such costs and expenses, in the aggregate, shall not exceed [] ofthe agreed-upon budget (as set forth above).3.10Right to Purchase Directly from Subcontractors or Second Source Suppliers.(a)If (i) a Force Majeure Event affecting solely Antares (specifically excluding its Subcontractors or Second SourceSuppliers) lasts for [] which prevents Antares from fulfilling its financial obligations to a Subcontractor or aSecond Source Supplier, or (ii) Antares is otherwise in material breach of its financial obligations to a Subcontractoror a Second Source Supplier for a period of at least [] then Antares shall promptly deliver to AMAG a writtennotice of such event or breach. Following the receipt of such notice, or following Antares’ material breach of itsobligation to deliver such notice under this Section 3.10(a), AMAG may deliver written notice to Antares of itsintention to exercise its rights under this Section 3.10.(b)For the period commencing on Antares’ receipt of such notice from AMAG as set forth in Section 3.10(a) andending [] thereafter, Antares and AMAG shall negotiate in good faith a commercially reasonable agreement withrespect to the Force Majeure Event or material breach describe in Section 3.10(a)(i) or 3.10(a)(ii), respectively,which may include, AMAG advancing payment for Manufacturing Services on terms to be negotiated among theParties (an “Alternate Arrangement”). If, following the expiration of such [] period, the Parties cannot mutuallyagree on a commercially- 18 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDreasonable agreement thereof, then, notwithstanding anything to the contrary in this Agreement, Antares shall use CommerciallyReasonable Efforts to enable AMAG to commence purchasing Devices, Components, Products, sample Products and/or Trainersdirectly from Antares’ Subcontractors or Second Source Supplier(s) on substantially similar terms, including price, that Antareshas with such Subcontractor or Second Source Supplier(s) (as the case may be). AMAG’s right to purchase Devices,Components, Products, sample Products and/or Trainers directly from Antares’ Subcontractor(s) or Second Source Supplier(s)shall continue to [].(c)Provided that (i) AMAG and Antares have agreed to the terms of an Alternate Arrangement, or (ii) AMAGcommences purchasing Devices, Components, Products, sample Products and/or Trainers directly from Antares’Subcontractors or Second Source Supplier(s) pursuant to the terms of Section 3.10(b), AMAG’s election of its rightto purchase Devices, Components, Products, sample Products and/or Trainers directly from Antares’Subcontractor(s) or Second Source Supplier(s) under this Section 3.10 shall be AMAG’s sole and exclusiveremedy, and Antares’ sole liability, with respect to Antares’ failure to supply such Devices, Components, Products,sample Products and/or Trainers for the reasons specified in Section 3.10(a); provided, that, if AMAG does notelect such right, AMAG shall not be prohibited from exercising all other rights available to AMAG under thisAgreement and at law.ARTICLE 4 PRICE AND PAYMENT4.1Prices.(a)During the Term, Antares or its Subcontractor shall deliver Products, sample Products and Trainers ordered byAMAG in accordance with this Agreement at the Transfer Prices set forth on Exhibit D.(b)[].4.2Invoices and Payment.[].4.3ecords; Financial Audit Request. With respect to audits of Antares’ records relating to the establishment of the Transfer Price,[] or any other amounts payable by AMAG hereunder, including, without limitation, pursuant to Section 4.6, Article 11 ofthe Development and License Agreement is hereby incorporated by reference herein and made a part of this Agreement.4.4axes.- 19 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(a)The Transfer Price includes all taxes except (i) such sales and use taxes which Antares is required by law to collectfrom AMAG and (ii) to the extent imposed on the date of this Agreement or as a result of a change in law, VAT.Such VAT and taxes, if any, will be payable in addition to the Transfer Price. Where Antares is required by law tocollect and/or account for such VAT and taxes from AMAG, such VAT and taxes will be separately stated inAntares’s Invoice and will be paid by AMAG to Antares unless AMAG provides an exemption to Antares and, inthe case of VAT, subject to Antares providing a valid VAT invoice to AMAG in the form and manner required by lawto allow AMAG to recover such VAT (to the extent AMAG is allowed to do so by law). For avoidance of doubt,any increase in VAT imposed as a result of any action taken by Antares, and not consented to by AMAG, after thedate of this Agreement shall not be paid by AMAG or otherwise included in the Transfer Price.(b)Except where AMAG is required by Applicable Law to account for any VAT to the applicable GovernmentalAuthority, Antares shall be solely responsible for the timely payment of all such VAT and taxes to the applicableGovernmental Authority(c)Notwithstanding the foregoing in this Section 4.4, AMAG shall be responsible for the payment of all duties, tariffs,VAT, taxes and similar charges payable on the exportation or importation of the Products, sample Products orTrainers. Without limiting any of Antares’s obligations hereunder, Antares shall cooperate with and assist AMAG inall aspects of the shipment, exportation, importation and delivery process in order to ensure the expeditious deliveryof the Product to the designated delivery point, including assisting in obtaining any documents that may be required.4.5].4.6].ARTICLE 5 PRODUCT CLAIMS AND RECALLS5.1Product Claims.(a)Product Claims. [].(b)Determination of Deficiency. [].(c)Shortages. [].5.2Product Recalls and Returns.- 20 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(a)Records and Notice. In addition to the requirements of Section 6.2, Antares and AMAG shall each maintain suchrecords in compliance with Applicable Laws as is reasonably necessary to permit a Recall of any Products, sampleProducts and Trainers delivered to AMAG, AMAG’s designee or customers of AMAG. Each Party shall promptly(but no later than [] of receipt of such information) notify the other by telephone (to be confirmed in writing) ofany information which might affect the marketability, safety, or effectiveness of the Products, sample Products orTrainers and/or which might result in the Recall or seizure of the Products, sample Products, or Trainers. Uponreceiving any such notice or upon any such discovery, each Party shall cease and desist from further shipments ofsuch Products, sample Products or Trainers in its possession or control until a decision by AMAG has been madewhether a Recall or some other corrective action is necessary.(b)Recalls. The decision to initiate a Recall or to take some other corrective action, if any, shall be made andimplemented by AMAG in its sole discretion after consultation with Antares. AMAG shall be responsible formanaging all Recalls and Antares shall cooperate with AMAG as AMAG may reasonably request. Subject toAntares’ obligation to cover the costs set forth in Section 5.3(b), AMAG shall be responsible for all costs incurreddue to the Recall of a Product, sample Product or Trainer.(c)Product Returns. AMAG shall have the responsibility for handling customer returns of the Products, sampleProducts and Trainers.5.3Antares’ Responsibility for Defective and Recalled Products.(a)Defective Product. [].(b)Recalled Product. [].5.4Disposition of Defective or Recalled Products. AMAG shall not dispose of any damaged, defective, returned orRecalled Products, sample Products or Trainers in relation to which it intends to assert a claim against Antares withoutAntares’ prior written authorization to do so, unless otherwise required by Applicable Laws. Alternatively, Antares mayinstruct AMAG to return such Products, sample Products and Trainers to Antares at Antares’ expense. Antares shall bearthe cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products or Trainersin relation to which it bears responsibility under Sections 5.1, 5.2 or 5.3 hereof. In all other circumstances, AMAG shallbear the cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products andTrainers.5.5Customer Questions or Complaints. AMAG shall have the sole right and responsibility for responding to questions andcomplaints from AMAG’s customers. Antares shall refer any questions and complaints (including safety and efficacyinquiries, quality complaints- 21 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDand adverse event reports) that it receives concerning the Device or the Products, sample Products or Trainers to AMAG(together with all available evidence and other information relating thereto) as soon as practicable and, in any event within [] ofAntares’ receipt of such question or complaint; provided that all complaints concerning Product and sample Product tampering,contamination or mix-up (e.g., wrong ingredients) shall be delivered within [] of Antares’ receipt thereof. Antares shall not takeany further action in connection with any such questions or complaints without the consent of AMAG, but shall cooperate in theinvestigation and closure of any such questions or complaints at the request of AMAG. Such assistance shall include follow-upinvestigations, including testing. In addition, Antares shall provide AMAG with all information to enable AMAG to respondproperly to questions or complaints relating to the Products and sample Products as provided in the Quality Agreement.ARTICLE 6 CO-OPERATION; QUALITY AUDIT; REGULATORY FILINGS6.1Governmental Agencies. Subject to the Regulatory Authority inspection obligations set forth in Section 6.3, Antaresand/or its Subcontractor(s) may communicate with any Regulatory Authority regarding the Products, sample Products andTrainers only if, in the reasonable opinion of Antares’ and/or its Subcontractor’s counsel, such communication is necessaryto comply with the terms of this Agreement or Applicable Laws; provided, however, that unless, in the reasonable opinionof Antares’ and/or its Subcontractor’s counsel, there is a legal prohibition against doing so, Antares shall notify AMAGreasonably in advance of any such communication and permit AMAG to accompany Antares and/or its Subcontractor andtake part in any communications with such Regulatory Authority, and provide AMAG with copies of all suchcommunications from such Regulatory Authority.6.2Records and Accounting by Antares. Antares shall keep records of the manufacture, testing and shipping of theProducts, sample Products and Trainers and retain samples of such Products, sample Products and Trainers as arenecessary to comply with cGMPs, Applicable Laws, the Quality Agreement, and manufacturing regulatory requirementsapplicable to Antares, as well as to assist with resolving Product, sample Product and Trainer complaints and other similarinvestigations. Copies of such records and samples shall be retained for the respective periods set forth in the QualityAgreement.6.3Regulatory Inspections. Antares shall permit the FDA and other Regulatory Authorities to conduct inspections of eachManufacturing Site as they may request, including pre-approval inspections, and shall cooperate with such RegulatoryAuthorities with respect to the inspections and any related matters, in each case which is related to the Device, Product orsample Product. Antares shall give AMAG notice within [] of becoming aware of any such inspections, and keepAMAG reasonably informed about the results and conclusions of each regulatory inspection, including actions taken byAntares or its Subcontractor to- 22 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDremedy conditions cited in the inspections, to the extent such results and conclusions relate to the Device, Product or sampleProduct. In addition, Antares will promptly provide AMAG with copies of any written inspection reports issued by RegulatoryAuthorities and all correspondence between Antares and Regulatory Authorities, including, but not limited to, FDA Form 483,Notice of Observation, and all related correspondence, in each case only to the extent relating to the Device, Product or sampleProduct or general manufacturing concerns related to the Device, Product or sample Product, which in all cases may bereasonably redacted by Antares to protect confidential information of Antares or its partners, licensees or licensors. Antaresagrees to promptly notify and provide AMAG copies of any request, directive or other communication of the FDA or otherRegulatory Authority relating to the Device, Product or sample Product and to reasonably cooperate with AMAG in respondingto such requests, directives and communications.6.4Quality Audit. The Parties rights and obligations with respect to quality assurance audits are set forth in the QualityAgreement.6.5Reports. Antares will promptly supply on an annual basis and when reasonably requested by AMAG from time to time, atno additional charge, all available information and data in its control that AMAG reasonably requires in order to completeany filing for, or apply for, obtain or maintain, regulatory approvals under any applicable regulatory regime (including anyAnnual Report that AMAG is required to file with the FDA), including without limitation information relating to theManufacturing Site, Development Report (as described in ICH guidelines), Manufacturing Services, Device, Product,sample Product, Trainers or the process, methodology, raw materials and intermediates used in the manufacture,processing, or packaging of the Device, Product, sample Product or Trainers, release test results, complaint test results, allinvestigations (in manufacturing, testing and storage), and all information required to be submitted in the CMC (chemistry,manufacturing and controls) section of an IND or a NDA or other regulatory filings, or required or requested to beprovided to any Regulatory Authority. At AMAG’s reasonable written request, Antares shall be responsible for supportingAMAG’s Annual Product Review Report, consistent with cGMPs, Applicable Laws, and customary FDA or otherRegulatory Authority requirements. Any additional report requested by AMAG beyond the scope of what is required orrecommended under cGMPs, Applicable Laws and customary FDA or other Regulatory Authority requirements shall besubject to an additional fee to be agreed upon between Antares and AMAG. In addition, Antares shall cooperate withAMAG with respect to all reporting obligations relevant to the Product, sample Product and Trainers under ApplicableLaws.6.6Regulatory Filings. Responsibility for regulatory filings shall be as set forth in Section 4.1 of the Development andLicense Agreement.- 23 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDARTICLE 7 TERM AND TERMINATION7.1Term. Subject to early termination of this Agreement pursuant to Sections 7.2, 7.3 or 7.4, this Agreement shall becomeeffective as of the Effective Date and shall continue until the expiration or earlier termination of the Development andLicense Agreement (the “Term”).7.2Termination By AMAG. This Agreement may be terminated in its entirety by AMAG, upon AMAG’s prior writtennotice to Antares:(a)Subject to Sections 11.1 and 12.4, if Antares commits a material breach of this Agreement and such material breachremains uncured for [] following written notice of breach by Antares. Notwithstanding the foregoing, AMAG’stermination rights with respect to an Antares’ failure to supply Products, sample Products or Trainers, including aSupply Failure, are not subject this Section 7.2(a) and are set forth in Section 7.2(b);(b)Subject to Section 12.4, if a Supply Failure remains uncured for [] following written notice of such failure toAntares; provided, however, that AMAG may not terminate this Agreement if Antares’ failure to supply Products,sample Products or Trainers is a result of Force Majeure Event under Section 12.4 or AMAG’s breach of thisAgreement including, but not limited to, failure to provide adequate quantities of Prefilled Syringe;(c)If Antares is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit ofcreditors, or is subject to the appointment of a receiver for all or a substantial part of Antares’ assets, and suchpetition, assignment or appointment prevents Antares (as a legal or as a practical matter) from performing itsobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacatedwithin []; or(d)Upon [] written notice to Antares in the event that AMAG permanently ceases commercializing the Product forefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List ofthe FDA Orange Book publication (“Approved Drug Products with Therapeutic Equivalence Evaluations”).7.3Termination by Antares. This Agreement may be terminated in its entirety by Antares upon Antares’ prior written noticeto AMAG:(a)Subject to Sections 11.1 and 12.4, if AMAG commits a material breach of this Agreement and such material breachremains uncured for [] following written notice of breach by Antares;- 24 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(b)If AMAG is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit ofcreditors, or is subject to the appointment of a receiver for all or a substantial part of AMAG’s assets, and suchpetition, assignment or appointment prevents AMAG (as a legal or as a practical matter) from performing itsobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacatedwithin []; or(c)Upon [] written notice to AMAG in the event that AMAG permanently ceases commercializing the Product forefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List ofthe FDA Orange Book publication (“Approved Drug Products with Therapeutic Equivalence Evaluations”).7.4Co-Termination. Without further action by either Party, this Agreement shall automatically terminate effective immediatelyupon the termination of the Development and License Agreement in its entirety, subject to the provisions that expresslysurvive the termination thereof.7.5Remedies for Material Breach.(a)Remedies for AMAG. Subject to Sections 11.1 and 12.4, in the event of an uncured material breach by Antares thatwould entitle AMAG to terminate this Agreement under Section 7.2(a) and Section 7.2(b), in addition to andindependent of AMAG’s right to terminate this Agreement, AMAG may seek monetary damages (whether or notthis Agreement is terminated) for such material breach and/or equitable relief to prevent such material breach fromcontinuing or occurring again in the future.(b)Remedies for Antares. Subject to Sections 11.1 and 12.4, in the event of a uncured material breach by AMAG thatwould entitle Antares to terminate this Agreement under Section 7.3(a), in addition to and independent of Antares’right to terminate this Agreement, Antares may seek monetary damages (whether or not this Agreement isterminated) for such material breach and/or equitable relief to prevent such material breach from continuing oroccurring again in the future.7.6Effects of Expiration or Termination of this Agreement.(a)If this Agreement expires or is terminated for any reason, then (in addition to any other remedies either Party mayhave in the event of material breach by the other Party):[].(b)[].(c)[].- 25 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(d)[].(e)Except with respect to AMAG’s right to sell off existing inventory as set forth in Section 7.6(d), the Partiesacknowledge and agree that following any expiration or termination of this Agreement, all rights and licenses grantedto AMAG under this Agreement or the Development and License Agreement shall terminate and AMAG shall ceaseusing and selling any Products, sample Products or Trainers.(f)Any termination or expiration of this Agreement shall not affect any outstanding obligations or payments duehereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the Parties may haveunder this Agreement or Applicable Laws (except as otherwise provided in this Agreement). For greater certainty,termination of this Agreement for any reason shall not affect the obligations and responsibilities of the Partiespursuant to ARTICLE 1 (Interpretation), ARTICLE 9 (Remedies and Indemnities) (provided that, the obligation tomaintain the insurance coverages set forth in Section 9.3 shall only survive for the time period set forth therein),ARTICLE 10 (Confidentiality), ARTICLE 11 (Dispute Resolution), and Sections 2.9 (Retained Samples) (for theperiod set forth therein), 4.4 (Taxes), 5.2 (Product Recalls and Returns); 5.5 (Customer Questions or Complaints)(for a period of [] from the date of termination or expiration); 6.2 (Regulatory and Accounting by Antares) (forthe period set forth therein), 7.6 (Effects of Expiration or Termination of this Agreement), 12.1 (Agency), 12.2(Assignment) 12.5 (Notices), 12.6 (Amendment), 12.7 (Waiver) and 12.10 (Governing Law), all of which surviveany termination or expiration.(g)Termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rightswhich shall have accrued to the benefit of either Party prior to (or as a result of, including, without limitation, rightsavailable under law and equity) such termination, relinquishment or expiration. Such termination, relinquishment orexpiration shall not relieve either Party from obligations that are expressly indicated to survive termination orexpiration of the Agreement.7.7 [].ARTICLE 8 REPRESENTATIONS, WARRANTIES AND COVENANTS8.1Authority. Each Party hereby represents, warrants and covenants to the other Party that: (i) it has the full right and authorityto enter into this Agreement and to grant to the other Party the rights granted to such other Party under this Agreement, (ii)it has obtained all necessary corporate approvals to enter and execute this Agreement, and (iii) that it is not aware of anyimpediment that would inhibit its ability to perform its obligations hereunder.- 26 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED8.2AMAG Warranties. AMAG hereby represents, warrants and covenants to Antares as follows:(a)AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall manufacture theDrug and Pre-Filled Syringe in accordance with the Specifications, cGLP, cGCP, cGMP and cQSRs, thisAgreement, the Quality Agreement and Applicable Laws including, without limitation, federal, state, or local laws,regulations, or guidelines governing manufacturing at the site where such manufacturing is being conducted;(b)AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall obtain andmaintain all necessary licenses, permits and approvals required by Applicable Laws in connection with themanufacture the Drug and Pre-Filled Syringe, and supply of Drug and Prefilled Syringes to Antares or itsSubcontractor;(c)That all Drug or Prefilled Syringes manufactured by AMAG, or a Third Person on behalf of AMAG, when deliveredto Antares or its Subcontractor (i) will comply with applicable Product Specifications and Certificate of Analysis(PFS Manufacture); (ii) will not be adulterated or misbranded within the meaning of any Applicable Laws effective atthe time of delivery and will not be an article which may not be introduced into interstate commerce under anyApplicable Laws; (iii) will be delivered to Antares or its Subcontractor (as the case may be) free and clear of all liensand encumbrances, and (iv) will be in compliance with cGMPs and all Applicable Laws;(d)That all Products and sample Products, when released by AMAG for distribution, sale or use pursuant to Section2.6(b)(v)(D): (i) will comply with applicable Product Specifications, Batch Record, Certificate of Analysis Certificateof Analysis (PFS Manufacture), the Certificate of Analysis (PFS ID Testing), Certificate of Analysis (Product) andthe Certificate of Conformance (Product); (ii) will not be adulterated or misbranded within the meaning of anyApplicable Laws effective at the time of delivery and will not be an article which may not be introduced intointerstate commerce under any Applicable Laws; and (iii) will be in compliance with cGMPs and all ApplicableLaws;(e)Prior to the first commercial sale by AMAG or a Third Person on behalf of AMAG of Products, sample Productand Trainers in a given market, the Products, sample Product and Trainers, if labelled and manufactured inaccordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws, have receivedthe necessary marketing approvals from applicable Regulatory Authorities for sale, distribution and use in suchmarket;- 27 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED(f)AMAG has the requisite legal title and ownership under its intellectual property necessary for it to fulfill its obligationsunder this Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, orgovernment investigation (and AMAG has not received any communication relating thereto) which alleges thatAMAG’s past activities relating to the Drug or activities proposed under this Agreement infringe or misappropriateany of the intellectual property rights of any Third Person, and to AMAG’s actual knowledge, there is no intellectualproperty of any Third Person that would be infringed or misappropriated by Antares or its Subcontractor carryingout the Manufacturing Services in accordance with this Agreement; and(g)AMAG agrees that federal securities law may prohibit it, its Affiliates and its representatives from purchasing orselling any securities of Antares while it is in possession of material, non-public information of Antares, and that it willnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouragingsuch party to trade in Antares’s securities and that it will comply at all times with the applicable securities laws andregulations.8.3Antares Warranties. Antares hereby represents, warrants and covenants to AMAG as follows:(a)Antares or its Subcontractor shall perform the Manufacturing Services in accordance with the Specifications, cGLP,cGCP, cGMPs and cQSRs, this Agreement, the Quality Agreement and Applicable Laws including, withoutlimitation, federal, state, or local laws, regulations, or guidelines governing manufacturing at the Manufacturing Sites;(b)Antares or its Subcontractor shall obtain and maintain all necessary licenses, permits and approvals required byApplicable Laws in connection with the Manufacturing Services, manufacture of Devices and supply of Products,sample Products or Trainers to AMAG;(c)As of the Effective Date, Antares has disclosed to AMAG any and all FDA Form 483’s, warning letters or similarnotices relating to the Manufacturing Site and import alerts for any other products manufactured in the ManufacturingSite issued during the last [];(d)[];(e)Antares has the requisite legal title and ownership of intellectual property necessary for it to fulfill its obligations underthis Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, orgovernment investigation (and Antares has not received any communication relating thereto) which alleges thatAntares’ past activities relating to [] devices or activities proposed under this- 28 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDAgreement infringe or misappropriate any of the intellectual property rights of any Third Person, and to Antares’ actualknowledge, there is no intellectual property of any Third Person that would be infringed or misappropriated by AMAG fulfillingany of its obligations or exercising any of its rights under this Agreement; and(f)Antares agrees that federal securities law may prohibit it, its affiliates and its representatives from purchasing orselling any securities of AMAG while it is in possession of material, non-public information of AMAG, and that it willnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouragingsuch party to trade in AMAG’s securities and that it will comply at all times with the applicable Federal SecuritiesLaws and regulations.(g)[].8.4Debarred Persons. Each of the Parties covenants, represents and warrants that: (i) neither it nor any of its employees or,subcontractors performing Manufacturing Services have been “debarred” by the FDA, or subject to a similar sanctionfrom another Regulatory Authority; nor have debarment proceedings against said Party or any of its employees orsubcontractors performing Manufacturing Services been commenced; and (ii) it will not in the performance of itsobligations under this Agreement use the services of any person debarred or suspended by the FDA as described in 21U.S.C. §335(a) or (b). Said Party will promptly notify the other Party in writing if any such debarment proceedings havecommenced or if said Party or any of its employees or subcontractors performing Manufacturing Services are debarred bythe FDA or other Regulatory Authorities. Each of the Parties further covenants, represents and warrants that it does notcurrently have, and will not hire, as an officer or an employee any person who has been convicted of a felony under thelaws of the United States for conduct relating to the regulation of any drug product under the Federal Food, Drug, andCosmetic Act.8.5Permits. As between the Parties, AMAG shall be solely responsible for obtaining or maintaining, on a timely basis, anypermits or other Regulatory Approvals in respect of the Products, sample Products, Trainers, Specifications, including,without limitation, all marketing and post-marketing approvals.8.6No Warranty. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EITHEREXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THISAGREEMENT, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF FITNESS FOR A PARTICULARPURPOSE OR WARRANTY OF MERCHANTABILITY OR WARRANTY OF NON-INFRINGEMENT OFTHIRD PERSON RIGHTS.- 29 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDARTICLE 9 REMEDIES AND INDEMNITIES9.1Antares’ Right to Indemnification. AMAG shall indemnify each of Antares, its Affiliates, its Subcontractors and theirrespective successors and assigns, and the directors, officers, employees, and agents thereof (the “AntaresIndemnitees”), defend and hold each Antares Indemnitee harmless from and against any and all liabilities, damages,losses, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation reasonableattorneys’ fees) (any of the foregoing, “Damages”) incurred by or asserted against any Antares Indemnitee of whateverkind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation ofgovernment regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurringas a result of a claim or demand made by a Third Person (a “Third Person Claim”) against any Antares Indemniteebecause of (a) breach of any warranty made by AMAG pursuant to Section 8.2 hereof; (b) the Product, sample Productor Trainer (including the content of any labelling and the decision to release the Product, sample Product or Trainer) unlessattributable to an item identified in Section 9.2 below which is under the responsibility of Antares or its Subcontractors; (c)the distribution or detailing of any Product, sample Product or Trainer by or on behalf of AMAG or its sublicensees,except to the extent such claim is attributable to an item identified in Section 9.2(f) below which is under the responsibilityof Antares; (d) any allegation that the manufacture, use, sale, offer for sale or importation of a Product, sample Product orTrainer infringes any patent, other intellectual property rights or other proprietary rights of a Third Person, except to theextent such infringement relates to the manufacture, use, sale, offer for sale or importation of a Device (including a Deviceincorporated into a Product) or any delivery system including the Device; or (e) any breach of this Agreement by AMAG,except, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence ormisconduct of Antares. Antares shall promptly notify AMAG of any Third Person Claim upon becoming aware thereof,and shall permit AMAG, at AMAG’s cost, to defend against such Third Person Claim and to control the defense anddisposition (including, without limitation, selection its counsel and all decisions to litigate, settle or appeal) of such claim,and shall cooperate in the defense thereof. Antares may, at its option and expense, have its own counsel participate in anyproceeding that is under the direction of AMAG and shall cooperate with AMAG and its insurer in the disposition of anysuch matter.9.2AMAG’s Right to Indemnification. Antares shall indemnify each of AMAG, its Affiliates, and their respectivesuccessors and assigns, and the directors, officers, employees, and agents thereof (the “AMAG Indemnitees”), defendand hold each AMAG Indemnitee harmless from and against any and all Damages incurred by or asserted against anyAMAG Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence,warranty, strict liability, violation of government regulation or infringement of- 30 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDpatent or other proprietary rights, but only to the extent arising from or occurring as a result of a Third Person Claim against anyAMAG Indemnitee because of (a) breach of any warranty made by Antares pursuant to Section 8.3 hereof; (b) any alleged defectin the design or functionality of the Device; (c) the failure by Antares or its Subcontractors to provide the Manufacturing Servicesaccording to Specifications, except to the extent AMAG approved such failure pursuant to its in process acceptance activities setforth in the Quality Agreement; (d) []; (e) the warehousing or shipping of a Product, sample Product or Trainer by Antares,except to the extent such claim alleges infringement of any patent, other intellectual property rights or other proprietary rights of aThird Person; (f) any allegation that the Manufacturing Services performed under this Agreement or the manufacture, use, sale,offer for sale or importation of a Device (including a Device incorporated into a Product) or any delivery system including theDevice, in such cases, infringes any patent, other intellectual property rights or other proprietary rights of a Third Person; or (g)any breach of this Agreement by Antares, except, in each such case, to the extent that such Damages are finally determined tohave resulted from the negligence or misconduct of AMAG or a sublicensee of AMAG. AMAG shall promptly notify Antares ofany Third Person Claim upon becoming aware thereof, and shall permit Antares at Antares’ cost to defend against such ThirdPerson Claim and to control the defense and disposition (including, without limitation, selection its counsel and all decisions tolitigate, settle or appeal) of such Third Person Claim and shall cooperate in the defense thereof. AMAG may, at its option andexpense, have its own counsel participate in any proceeding that is under the direction of Antares and will cooperate with Antaresor its insurer in the disposition of any such matter.9.3Insurance. Each Party shall obtain and maintain commercial general liability insurance, including product liability insurancecovering the obligations of that Party under this Agreement through the Term and for a period of [] thereafter, whichinsurance shall afford limits of not less than (i) [] for each occurrence; and (ii) [] in the aggregate per annum.Such insurance may be provided in more than one separate insurance policy and/or on claims made or claims made andreported forms as is common in the insurance marketplace for similar risks. If requested each Party will provide the otherwith a current and valid certificate of insurance evidencing the above and showing the name of the issuing company, thepolicy number, the effective date, the expiration date and the limits of liability. If a Party is unable to maintain the insurancepolicies required under this Agreement through no fault on the part of such Party, then such Party shall forthwith notify theother Party in writing and the Parties shall in good faith negotiate appropriate amendments to the insurance provision of thisAgreement in order to provide adequate assurances.9.4Limitation of Liability.[].- 31 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDARTICLE 10 CONFIDENTIALITYArticles 17 and 18 of the Development and License Agreement are hereby incorporated by reference herein and made a part ofthis Agreement.ARTICLE 11 DISPUTE RESOLUTION11.1Commercial Disputes. In the event of any dispute arising out of or in connection with this Agreement [], the Partiesshall first try to solve it amicably. In this regard, any Party may send a notice of dispute to the other, and each Party shallappoint, within [] from receipt of such notice of dispute, a senior executive representative having full power andauthority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute. Ifthe dispute has not been resolved within [] after the end of the [] negotiation period referred to above (whichperiod may be extended by mutual agreement), then such dispute shall be subject to any other remedy available under thisAgreement or at law or equity.11.2[].ARTICLE 12 MISCELLANEOUS12.1Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the otherParty for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the otherParty, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having theauthority to do so.12.2Assignment. Except as otherwise provided in this Section 12.2, neither this Agreement nor any interest hereunder shall beassignable by any Party without the prior written consent of the other (which consent shall not be unreasonably withheld,conditioned or delayed); provided, however, that either Party may assign this Agreement to any wholly-owned subsidiaryor to any successor by merger or sale of substantially all of its business unit to which this Agreement relates. ThisAgreement shall be binding upon the successors and permitted assignees of the Parties. Any purported assignment inviolation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to thepurported assignee.12.3Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all suchother acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.- 32 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED12.4Force Majeure. Neither Party shall be liable to the other for loss or damages or shall have any right to terminate thisAgreement for any default or delay attributable to any force majeure event outside of the affected Party’s reasonablecontrol, including, but not limited to, acts of God, acts of government, war, fire, flood, earthquake, terrorist acts, strike,labor dispute and the like (each, a “Force Majeure Event”), if the Party affected shall give prompt notice of any suchcause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder asit is disabled by the Force Majeure Event from performing for so long as it is so disabled; provided, however, that suchaffected Party commences and continues to take reasonable and diligent actions to cure such cause throughout suchdisability.12.5Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if deliveredpersonally or by electronic mail or facsimile transmission (receipt verified), telexed, mailed by registered or certified mail(return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (orat such other address for a Party as shall be specified by like notice; provided, that notices of a change of address shall beeffective only upon receipt thereof):If to AMAG, addressed to:AMAG Pharmaceuticals, Inc.[]1100 Winter StreetWaltham, MA 02451[]With a copy to:[]AMAG Pharmaceuticals, Inc.100 Winter StreetWaltham, MA 02451[]If to Antares, addressed to:Antares Pharma, Inc.[]100 Princeton South, Suite 300Ewing, NJ 08628[]with a copy to:General CounselAntares Pharma, Inc.100 Princeton South, Suite 300Ewing, NJ 08628[]- 33 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED12.1Amendment. No amendment, modification or supplement of any provision of the Agreement shall be valid or effectiveunless made in writing and signed by a duly authorized officer of each Party.12.2Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents oremployees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer ofthe waiving Party. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in anyone or more instances shall be deemed to be or construed as a further or continuing waiver of any such term, provision orcondition or of any other term, provision or condition of this Agreement.12.3Counterparts; Electronic Copies. The Agreement may be executed simultaneously in two or more counterparts, eitherone of which need not contain the signature of more than one Party but both such counterparts taken together shallconstitute one and the same agreement. A facsimile transmission or portable document format (PDF) electronictransmission of this signed Agreement by a Party’s authorized representative shall be legal and binding upon such Party.12.4Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force oreffect in construing or interpreting any of the provisions of this Agreement.12.5Governing Law; Choice of Forum. This Agreement shall be governed by and interpreted in accordance with thesubstantive laws of the State of New York, without regard to its conflict of law provisions. The Parties agree that theUnited Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement. Except asotherwise provided in ARTICLE 11, all claims and proceedings under this Agreement shall be brought exclusively in thestate or federal courts of competent subject matter jurisdiction in New York City, State of New York. The Parties herebywaive (i) any objection which it may have at any time to the venue of the proceeding in any such court, (ii) any claim thatsuch proceedings have been brought in an inconvenient forum, and (iii) the right to object, with respect to suchproceedings, that such court does not have any jurisdiction over such Party.12.6Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effectiveand valid under Applicable Law, but if any provision of the Agreement is held to be prohibited by or invalid underApplicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating theremainder of the Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceableprovision that preserves the original purpose of this Agreement.- 34 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED12.7Entire Agreement of the Parties. This Agreement, including the Exhibits attached hereto, the Quality Agreement and theDevelopment and License Agreement constitute and contain the complete, final and exclusive understanding and agreementof the Parties hereto, and cancels and supersedes any and all prior negotiations, correspondence, understandings andagreements, whether oral or written, between the Parties respecting the subject matter hereof. In the event there is adiscrepancy between the Exhibits and the Agreement, the Agreement shall control, provided that to the extent there is adiscrepancy between the Quality Agreement and the Agreement, the Quality Agreement shall control with respect toquality-related matters; and this Agreement shall control with respect to all other matters. Furthermore, to the extent thatany provision of this Agreement is inconsistent with any provision of the Development and License Agreement, thisAgreement shall control and then only to the extent of the inconsistency. For the avoidance of doubt, this Agreementsupersedes and replaces Sections 10.2 and 10.3 of the Development and License Agreement.12.8Jointly Prepared. This Agreement has been prepared jointly by both Parties and shall not be strictly construed againsteither Party.[Signature page follows.]- 35 -[] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDIN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Agreement as of the datefirst written above.ANTARES PHARMA, INC.By: /s/ Patrick MadsenName: Patrick MadsenTitle: Senior Vice President, OperationsAMAG PHARMACEUTICALS, INC.By: /s/ William K. HeidenName: William K. HeidenTitle: President and Chief Executive Officer[Signature Page to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT ALONG LEAD TIME MATERIALSPart NameMaterial SpecificationLead-Time[][][][][][][][][][][][][][][][][][][][][][][][][][][][][][Exhibit A to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT BPRODUCT SPECIFICATIONS[][Exhibit B to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT CTRAINER SPECIFICATIONS[][Exhibit C to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT DTRANSFER PRICEThe “Transfer Price” to be paid by AMAG to Antares for each Product, sample Product and Trainer delivered to AMAG orAMAG’s designee under this Agreement during the Term shall be determined as follows:[][Exhibit D to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT EQUALITY AGREEMENT[][Exhibit E to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT FBATCH NUMBERING AND EXPIRATION DATES[][Exhibit F to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT GRETAINED SAMPLESPart NumberDescription[][][][][][][][][Exhibit G to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT HINITIAL FORECAST[][Exhibit H to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT IREDUNDANCY PLANItemFinancial ResponsibilityPrimaryBack-up On Hand[][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][Exhibit I to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT J[][Exhibit J to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT KAMAG EQUIPMENTThe following molds:Part NumberDescription[][][][][][][Exhibit K to Manufacturing Agreement][] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALLSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDEXHIBIT LFORM OF CHANGE ORDER[][Exhibit L to Manufacturing Agreement]